Quest Diagnostics Incorporated, listed as NYSE:DGX, is a leading provider in the medical diagnostics industry, specifically within the Zacks Medical - Outpatient and Home Healthcare sector. The company is known for its comprehensive diagnostic testing services, which are crucial for patient care and medical decision-making.
Quest Diagnostics competes with other major players in the healthcare diagnostics field, striving to maintain its position through consistent performance and innovation. On July 22, 2025, DGX is scheduled to release its quarterly earnings, with Wall Street anticipating earnings per share (EPS) of $2.57 and revenue of approximately $2.73 billion. Historically, Quest Diagnostics has a strong track record of surpassing earnings estimates, which makes it a promising candidate for continuing this trend.
In the last two quarters, DGX exceeded earnings estimates by an average of 2.31%, showcasing its ability to outperform market expectations. In the most recent quarter, DGX reported earnings of $2.21 per share, surpassing the Zacks Consensus Estimate of $2.15 per share, resulting in a 2.79% surprise. The previous quarter also saw DGX outperform expectations, with earnings of $2.23 per share against an expected $2.19 per share, achieving a 1.83% surprise. This consistent performance positions DGX favorably for potentially beating estimates again in its upcoming earnings report. DGX's financial metrics provide further insight into its market valuation and financial health.
The company has a price-to-earnings (P/E) ratio of approximately 20.65, indicating how much investors are willing to pay for each dollar of earnings. Its price-to-sales ratio stands at about 1.83, reflecting the market's valuation of its revenue. Additionally, the enterprise value to sales ratio is around 2.46, which considers the company's total valuation in relation to its sales. Quest Diagnostics also maintains a solid financial position with an earnings yield of about 4.84%, which indicates the return on investment for shareholders. The debt-to-equity ratio is approximately 0.95, showing a balanced approach to financing its assets. Furthermore, the current ratio of about 1.44 suggests that DGX is well-positioned to cover its short-term liabilities with its short-term assets, highlighting its financial stability.
